Ukulinganisa i-CRP Kungaba Okubalulekile Emzimbeni Wakho We-Cardiac
Ukulinganisa amazinga we-protein e-C-actif (CRP) angasiza ekuhloleni ingozi ye- coronary artery disease (CAD) kwabanye abantu. I-CRP iyi-protein ekhishwa egazini ngesikhathi se-inflammation. Njengoba ukuvuvukala manje sekuyaziwa ukuthi kudlala indima enkulu ekuthuthukiseni isifo sokuqina kwesifo sofuba (inqubo eyenza ama- plaques emithanjeni), kunengqondo ukuthi amazinga e-CRP angaphakanyiswa phakathi nezinkathi zokubunjwa kweplate futhi amazinga aphezulu e-CRP azohambisana izenzakalo zenhliziyo.
Izifundo manje sezibonise ukuthi i-CRP ephakeme ihlotshaniswa nengozi eyandayo yemicimbi ye-cardiovascular, njenge- heart attack and stroke . Kungakhathaliseki ukuthi i-CRP empeleni ibangela ingozi ekhulayo noma umane nje umaka wengozi isaphikisana, nakuba ukuphazamiseka kobufakazi kubonisa ukuthi akuyona imbangela eqondile. Noma kunjalo, manje sekuyaziwa ukuthi ukwelapha abantu abanamazinga aphezulu e-CRP abanesimiso kunganciphisa ingozi yabo. Leli qiniso lodwa lenza ukulinganisa i-CRP okungenzeka kuzuze kwabanye abantu.
I-CRP ilinganiselwa kanjani?
I-CRP ilinganiswa ngokusebenzisa ukuhlolwa okuphezulu kokuzwela (okubizwa ngokuthi i-hs-CRP test blood). Ngokuvamile, izinga eliphezulu le-hs-CRP, liphakeme kakhulu engozini. Amazinga we-hs-CRP ngezansi 1 abhekwa njengephansi; amazinga ka-1 kuya ku-3 abhekwa njengokuphakanyiswa ngokulinganisela; amazinga amakhulu kunama-3 abhekwa njengephezulu. Izinga eliphakeme kunezingu-10 zivame ukubonakala ngenqubo esebenzayo, ebonakalayo yokuvuvukala, njengokutheleleka okukhulu, ukuhlukunyezwa okukhulu, noma izifo ezingavamile zokuvuvukala - la mazinga aphakeme kakhulu angeke asetshenziselwe ukuhumusha ingozi yenhliziyo .
Ngenxa yokuthi amazinga e-CRP angashintsha ngokuhamba kwesikhathi, ochwepheshe abaningi manje bancoma ukulinganisa amazinga amabili e-CRP amasonto ambalwa ngaphandle nokwehlukanisa amanani amabili.
Ukunquma ukuthi ukulinganisa i-CRP kufanele kube yingxenye yenkambiso yokuhlola njalo kwaba nzima ngezizathu ezimbili. Okokuqala, ukuhumusha ukubaluleka kwezinga eliphezulu le-CRP ngokuvamile akuyona into eqondile, futhi kungaholela ekudidekeni okungaphezu kokungaphansi.
Okwesibili, kuze kube yamuva akucaci ukuthi ngabe ukwelashwa kufanele kushintshwe kunoma ubani ngokususelwa kwimiphumela yamanani we-CRP.
Kuyini Kuwusizo Ukulinganisa i-CRP?
Amazinga aphakeme we-CRP avame ukuhlobana nokuba khona kwamanye amathrekhi amaningi okubhekana nesifo senhliziyo ezifana nokubhema, ukukhuluphala, ukuphila ngokwemvelo , ukwanda kwe-cholesterol, umfutho wegazi ophezulu kanye nesifo se-metabolic syndrome . Amazinga aphakeme kakhulu e-CRP avame ukubonwa ezigulini ezinenani eliphezulu kakhulu lezinto eziyingozi ezingeziwe. Kulezi zimo, ukuthola izinga eliphezulu le-CRP liqinisekisa nje ukuthi yini ebonakalayo kakade - isiguli sinengozi enkulu yesifo senhliziyo , futhi sidinga ukuguqulwa kwesisindo esiyingozi (okungenzeka kufaka phakathi ama-statins) noma ngabe yiziphi izigaba zabo ze-CRP.
Ngakolunye uhlangothi, i-CRP ephakeme kakhulu kumuntu onomunye owodwa noma ezimbili ezinye izinto eziyingozi engeza ulwazi olungabalulekile. Kulaba bantu, izinga eliphezulu le-CRP kubonakala sengathi libonisa ukuthi ingozi yabo iphakeme kunokuba ibonakale. Kusho ukuthi kancane kancane kokushisa komfutho wegazi, noma isisindo esincane esengeziwe, kuhlobene ngempela nokuvuvukala emithanjeni yegazi nokuthi ingozi yemicimbi ye-cardiovascular ingaphakanyiswa.
Ngakho-ke, okungenani, ukuba ne-CRP ephakeme kufanele wenze wena nodokotela wakho kube nzima kakhulu ngokunciphisa ingozi. Ngaphezu kwalokho, idatha evela ku- JUPITER yamuva nje isitshela ukuthi ukunikeza izitembu kumagciwane avele aphilile anamazinga aphakeme e-CRP angakwazi ukunciphisa kakhulu futhi engabonakali kakhulu ingozi yesifo senhliziyo.
Okubalulekile
Amazinga e-CRP akudingeki ukuba alinganiswe kuwo wonke umuntu. Ngaphambi kokuba ucabangele ukulinganisa kwe-CRP, wena nodokotela wakho kufanele uhlole ingozi yakho yokuqala yesifo senhliziyo, ngokusekelwe ezingozini ezicacile ezingozi . Lokhu kuhlola kuzokutshela ukuthi usezingeni eliphezulu, eliphakathi noma eliphansi.
Uma usuvele usezingeni eliphezulu kakhulu, ukulinganisa i-CRP ngeke kube usizo kakhulu. Kungenzeka ukuthi unesifo senhliziyo noma uhlangothi oluthi uma unciphisa kakhulu ingozi yakho, kungakhathaliseki ukuthi i-CRP yakho ingaba yini. Kodwa uma wena noma udokotela wakho unqikaza ukusebenzisa i- statins , futhi ungaqiniseki ngenzuzo abangakunika yona, bese ulinganisa amazinga akho e-CRP angakunika isizathu esengeziwe sokucabangela lezi zidakamizwa zokunciphisa ingozi.
Kunengqondo kakhulu ukukala izinga le-CRP uma usezingeni eliyingcingo eliyingcingo. I-CRP ephakeme lapha kufanele ithumele amaflegi abomvu ukuthi ingozi yakho cishe iphezulu kunalokho ucabanga. Futhi, uma amazinga akho e-cholesterol ejwayelekile noma aphakanyiswe kancane, ukwazi ukuthi i-CRP yakho iphezulu ingakunikeza wena nodokotela wakho isizathu esicacile sokucabangela ukwelashwa nama-statins.
Ngombuso wanamuhla wanolwazi, ukubaluleka kokulinganisa amazinga e-CRP kubantu abasigaba esingozi kakhulu kuyacaca kakhulu. Uma i-CRP iphakanyisiwe futhi ungenayo ezinye izici eziyingozi, ukusebenzisa izitembu kungacatshangwa kodwa kuyinkinga enkulu. Odokotela abaningi bayavuma ukuthi kunesizathu esincane kakhulu sokukala amazinga e-CRP kubantu abakusezingeni eliphansi.
Uma unayo i-CRP yakho kulinganiswa futhi ibuya phezulu, ungase ufune ukufunda lesi sihloko: Okuzokwenziwa Uma i-CRP yakho iphakanyisiwe.
Imithombo:
I-Cook NR, i-Buring JE, ne-Ridker PM. Umphumela wokufaka iprotheyini esebenzayo ye-C ezinhlobonhlobo zokubikezela izinhlekelele zomzimba zabesifazane. U-Ann Intern Med 2006; 145: 21-29.
U-Lloyd-Jones DM, u-Liu K, u-Tian L, no-Greenland P. Ukubuyekezwa okulandelanayo: Ukuhlolwa kweprotheyini esebenzayo e-C ekubikezelweni kwezinengozi zesifo senhliziyo. U-Ann Intern Med 2006; 145: 35-42.
UDavey Smith G, uTimpson N no-Lawlor D. C-amaprotheni asebenzayo kanye nesifo sengqondo senhliziyo: Noma kunjalo engaziwa? U-Ann Intern Med 2006; 145: 70-72.
Ridker PM, uDanelson E, uFonseca FA et al. I-Rosuvastatin ukuvimbela izenzakalo zamathambo emadodeni nakwabesifazane abaneprotheyini ephakeme e-C. I-Engl J Med 2008; I-DOI: 10.1056 / NEJMoa0807646. Itholakala ku-: http://www.nejm.org.